Edition:
United States

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

85.10USD
16 Feb 2018
Change (% chg)

$-0.35 (-0.41%)
Prev Close
$85.45
Open
$85.40
Day's High
$85.48
Day's Low
$85.10
Volume
993,118
Avg. Vol
893,008
52-wk High
$86.28
52-wk Low
$19.62

Select another date:

Fri, Feb 2 2018

BRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics

* CELGENE CORPORATION COMMENCES TENDER OFFER FOR JUNO THERAPEUTICS, INC.

Bluebird CAR-T still top Celgene priority after Juno deal

Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio .

UPDATE 3-Bluebird CAR-T still top Celgene priority after Juno deal

Jan 25 Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio.

Celgene to buy Juno for $9 billion to boost cancer pipeline

Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video

UPDATE 3-Celgene to buy Juno for $9 bln to boost cancer pipeline

* Juno's CAR-T drug could rake in $3 bln worldwide in peak sales (Adds background and analyst quote, updates share price)

WRAPUP 2-Biotech M&A takes off as Sanofi and Celgene spend $20 billion

* Large drugmakers scour for products from smaller biotechs (Adds detail on gains in other biotech shares)

BRIEF-Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To Celgene

* JUNO THERAPEUTICS SAYS IF DEAL TERMINATED BY CO OR CELGENE UPON SPECIFIED CONDITIONS, FEE OF $300 MILLION MAY BE PAYABLE BY CO TO CELGENE - SEC FILING

Deals of the day-Mergers and acquisitions

Jan 22 The following bids, mergers, acquisitions and disposals were reported by 1145 GMT on Monday:

Celgene to buy remaining stake in Juno for $9 billion

Jan 22 Celgene Corp said on Monday it agreed to buy rest of Juno Therapeutics Inc for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.

BRIEF-Celgene To Acquire Remaining Shares Of Juno Therapeutics For $87 Per Share

* CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY

Select another date: